openPR Logo
Press release

COVID-19 Competitive Landscape 2024 (Updated) | Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, and others.

04-15-2024 05:42 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

COVID-19 Competitive Landscape

COVID-19 Competitive Landscape

DelveInsight's, "COVID-19 Competitive Landscape 2024" report provides comprehensive insights about 400+ COVID-19 Companies and 500+ drugs in Covid-19 Competitive landscape. It covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the COVID-19 Report
• DelveInsight's COVID-19 report depicts a robust space with 400+ active players working to develop 500+ pipeline therapies for COVID-19 treatment.
• The leading companies working in the COVID-19 Market include Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others.
• Promising COVID-19 therapies in the various stages of development includes XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others.
• November 2023: AstraZeneca announced a study of Phase 3 clinical trials for AZD7442. This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
• November 2023: BioNTech SE announced a study of Phase 1 clinical trials for BNT162b4 5 µg. The trial will use a staggered dosing process schema, i.e., enrollment into the next higher dose level is done sequentially and subject to safety data from the previous dose levels, with sentinel participants in Cohorts 1, 2, 3a, and 4a. Cohort 3b investigating the same dose level as Cohort 3a but in participants aged >55 years will be opened after safety data for participants aged 18-55 years in Cohort 3a has been reviewed.

Request a sample and discover the recent advances in COVID-19 Drugs @ COVID-19 Competitive Landscape Report- https://www.delveinsight.com/sample-request/covid-19-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The COVID-19 report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the COVID-19 report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

COVID-19 Overview
Coronaviruses are a large family of viruses that can cause illness in animals or humans. In humans several known coronaviruses cause respiratory infections. These coronaviruses range from the common cold to more severe diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19.

Find out more about COVID-19 Analytical Perspective: In-depth Commercial Assessment @ COVID-19 Collaboration Analysis by Companies- https://www.delveinsight.com/sample-request/covid-19-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

COVID-19 Companies and Therapies
• Nobelpharma: Sargramostim
• Staidson (Beijing) Biopharmaceuticals Co., Ltd: BDB-001
• NeuroActiva Inc.: NA-831
• Nanogen Pharmaceutical Biotechnology: Nanocovax

COVID-19 Competitive Landscape
The COVID-19 report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

COVID-19 Report Assessment
• Company Analysis
• COVID-19 Therapeutic Assessment
• COVID-19 Pipeline Assessment
• Inactive drugs assessment
• COVID-19 Unmet Needs

Learn more about the emerging COVID-19 Competitive Landscape @ COVID-19 Market Drivers and Barriers, Unmet Needs- https://www.delveinsight.com/sample-request/covid-19-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the COVID-19 Report
• Coverage- Global
• COVID-19 Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• COVID-19 Companies- Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others.
• COVID-19 therapies- XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others.

Dive deep into rich insights for new drugs for COVID-19 Product Developmental Activities, Visit @ COVID-19 Research and Development Activities- https://www.delveinsight.com/sample-request/covid-19-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. COVID-19: Overview
4. COVID-19 -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. COVID-19: Company and Product Profiles (Marketed Therapies)
8. AstraZeneca
9. AZD1222
10. COVID-19: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Vicore Pharma
13. C21
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Company Name
17. Product Name
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Enanta Pharmaceuticals
21. EDP 235
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. COVID-19- Unmet needs
29. COVID-19 - Market drivers and barriers
30. Appendix

For further information on the COVID-19 Report @ COVID-19 Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/covid-19-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
https://www.bestadsontv.com/profile/462518/Denny-Dones
https://manybooks.net/user/denny-dones
https://topbazz.com/germanydennydones
https://wibki.com/dennydones1
https://onlineghibli.com/tavern/members.php?mode=profile&userid=12548&boardid=1
https://www.undrtone.com/germanydennydon
https://solo.to/germanydennydones
https://app.geniusu.com/users/2455075
https://forum.alidropship.com/members/germanydennydones.50354/#about
https://pantip.com/profile/7306022#topics
https://pubhtml5.com/homepage/npvs/preview
https://doodleordie.com/profile/germanydennydones
https://www.rafabasa.com/author/germanydennydones/
https://www.tabletennisdaily.com/forum/members/germanydennydones.122613/#about
https://nhattao.com/members/user6331540.6331540/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release COVID-19 Competitive Landscape 2024 (Updated) | Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, and others. here

News-ID: 3464536 • Views:

More Releases from DelveInsight Business Research LLP

Glioblastoma Market Size in the 7MM is approximately USD XX Million in 2023, estimates DelveInsight
Glioblastoma Market Size in the 7MM is approximately USD XX Million in 2023, est …
The Glioblastoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2034). Furthermore, launching various multiple- Glioblastoma pipeline products will significantly revolutionize the Glioblastoma market dynamics" The Glioblastoma market report provides current treatment practices, Glioblastoma emerging drugs, market share of individual therapies, and current and forecasted 7MM Glioblastoma market size from 2020 to 2034. The report also covers current Glioblastoma treatment market practices/algorithms
Chronic Hepatitis B Market Size was approximately USD 1,500 Million in 2022, estimates DelveInsight
Chronic Hepatitis B Market Size was approximately USD 1,500 Million in 2022, est …
"The Chronic Hepatitis B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2034). Furthermore, launching various multiple- Chronic Hepatitis B pipeline products will significantly revolutionize the Chronic Hepatitis B market dynamics" The Chronic Hepatitis B market report provides current treatment practices, Chronic Hepatitis B emerging drugs, market share of individual therapies, and current and forecasted 7MM a Chronic Hepatitis B market size
Alopecia Areata Pipeline, Clinical Trials Assessment, and FDA Approvals 2024 (Updated)
Alopecia Areata Pipeline, Clinical Trials Assessment, and FDA Approvals 2024 (Up …
DelveInsight's, "Alopecia Areata Pipeline Insight 2024" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Alopecia Areata pipeline landscape. It covers the Alopecia Areata pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Alopecia Areata Pipeline Report •
Plaque Psoriasis Pipeline Insights, FDA Approvals, Clinical Trials Assessment, and Companies 2024
Plaque Psoriasis Pipeline Insights, FDA Approvals, Clinical Trials Assessment, a …
DelveInsight's, "Plaque Psoriasis Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Plaque Psoriasis pipeline landscape. It covers the Plaque Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Plaque Psoriasis Pipeline Report •

All 5 Releases


More Releases for Pharma

Antiemetics Market Size 2022 Analysis by Top Key Players| Acacia Pharma Group Pl …
Antiemetics Market research added by the Absolute Markets Insights, offers a comprehensive analysis of growth trends prevailing in the global business domain. This report also provides definitive data concerning market, size, commercialization aspects and revenue forecast of the industry. In addition, the study explicitly highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion endeavors. Access the PDF sample of the report@
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the
Indometacin Market Top Key Manufacturers Aidarex, Ratiopharm, Merck, Xinhua Phar …
The Global Indometacin Market is a nonsteroidal anti-inflammatory drug commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. The demand for nonsteroidal anti-inflammatory drug has been increasing owing to the emergence of anti-inflammatory biologics that are more targeted. However, such as side effects of anti-inflammatory drugs and patent expiry issues may hamper the market growth in the review period. For More Info, Get Sample Report
Hydroxycarbamide Market Study Report 2019| Taj Pharma, Beijing Jialin Pharma, Qi …
Los Angeles, United State, June 11, 2019, - The global Hydroxycarbamide market is expected to surge at a steady CAGR in the coming years, states the latest QY Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Hydroxycarbamide
TIGLUTIK Market 2019: Top Players are Sanofi, Mylan Pharma, Apotex, Glemark Gene …
TIGLUTIK Market 2019 Report analyses the industry status, size, share, trends, growth opportunity, competition landscape and forecast to 2025. This report also provides data on patterns, improvements, target business sectors, limits and advancements. Furthermore, this research report categorizes the market by companies, region, type and end-use industry. Get Sample Copy of this Report@ https://www.researchreportsworld.com/enquiry/request-sample/13709986 Global TIGLUTIK market 2019 research provides a basic overview of the industry including definitions, classifications, applications